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Abstract
As one of the largest protein families, protein kinases (PKs) regulate nearly all processes within the cell and are considered
important drug targets. Much research has been conducted on inhibitors for PKs, leading to a wealth of compounds that
target PKs that have potential to be lead anthelmintic drugs. Identifying compounds that have already been developed to
treat neglected tropical diseases is an attractive way to obtain lead compounds inexpensively that can be developed into
much needed drugs, especially for use in developing countries. In this study, PKs from nematodes, hosts, and DrugBank
were identified and classified into kinase families and subfamilies. Nematode proteins were placed into orthologous groups
that span the phylum Nematoda. A minimal kinome for the phylum Nematoda was identified, and properties of the minimal
kinome were explored. Orthologous groups from the minimal kinome were prioritized for experimental testing based on
RNAi phenotype of the Caenorhabditis elegans ortholog, transcript expression over the life-cycle and anatomic expression
patterns. Compounds linked to targets in DrugBank belonging to the same kinase families and subfamilies in the minimal
nematode kinome were extracted. Thirty-five compounds were tested in the non-parasitic C. elegans and active compounds
progressed to testing against nematode species with different modes of parasitism, the blood-feeding Haemonchus
contortus and the filarial Brugia malayi. Eighteen compounds showed efficacy in C. elegans, and six compounds also showed
efficacy in at least one of the parasitic species. Hypotheses regarding the pathway the compounds may target and their
molecular mechanism for activity are discussed.
Citation: Taylor CM, Martin J, Rao RU, Powell K, Abubucker S, et al. (2013) Using Existing Drugs as Leads for Broad Spectrum Anthelmintics Targeting Protein
Kinases. PLoS Pathog 9(2): e1003149. doi:10.1371/journal.ppat.1003149
Editor: Timothy G. Geary, McGill University, Canada
Received June 2, 2012; Accepted November 29, 2012; Published February 14, 2013
Copyright:  2013 Taylor et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The bioinformatic analysis and in vitro testing in C. elegans and H. contortus were supported by NIH AI081803 (MM). Brugia malayi life cycle and culture
work for testing compounds in B. malayi was supported by funds from Barnes Jewish Hospital Foundation grant (Dr. Gary Weil). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that they have no competing interests.
* E-mail: mmitreva@genome.wustl.edu
Introduction
Abnormal and unregulated phosphorylation in signaling path-
ways can lead to diseases, such as cancer, diabetes, immunodefi-
ciency, inflammation, and neurological disorders [1,2]. Phosphor-
ylation and dephosphorylation of proteins carried out by kinases
and phosphatases regulate almost every activity in the cell [3].
Protein kinases (PKs) account for 2% of eukaryotic genomes [4] and
are considered viable drug targets because the catalysis mechanism
and overall structure of PKs are conserved. Further, it is well
established that small molecules can bind to their catalytic cleft [5].
Hence, many kinase inhibitors have been developed to treat various
human diseases, including drugs such as imatinib, trastuzumab, and
lapatinib [2]. Understanding PKs can enable a deeper understand-
ing of how signaling pathways effect development, pathology and
biochemistry of an organism and also lead to more efficacious drugs
[6]. In fact, PKs are considered the second most important group of
drug targets after G-protein coupled receptors and are the largest
enzyme family [3]. Although toxicity has been a concern in some
cases, many drugs that target PKs have been approved for treating
various diseases, despite some lacking specificity [3].
Given the importance of PKs in drug development, bioinfor-
matics approaches and classification metrics have been developed
to gain a greater understanding of PKs and PK inhibitors. PKs can
be split into two diverse groups, with one group consisting of
‘‘conventional’’ PKs (ePKs) and the other comprised of ‘‘atypical’’
PKs (aPKs). The ePKs are the largest group and can be subdivided
into 8 families and multiple subclasses using a multi-level hidden
Markov model library [7]. The library consists of the following
ePK classifications: the AGC family, CAMKs, the CK1 family, the
CMGC family, the RGC family, the STE family, the TK family,
and the TKL family. Proteins that do not fit into any of these
classes are classified as other. The four aPK classifications consist
of Alpha, PIKK, PHDK, and RIO. The multi-level library
approach outperforms both BLASTP- and a Pfam HMMmodel-
based approach in retrieving kinases and classifying them on a
family level [7].
The World Health Organization estimates that over 2 billion
people are infected with parasitic worms [8]. Further, parasitic
worms also infect livestock and crops, which has deleterious effects
on food production and has a negative economic impact
worldwide [8]. Nematodes are becoming resistant to currently
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available anthelminthics and pesticides, thereby creating an urgent
need to develop new compounds to combat these parasites [9,10].
Protein kinases in nematodes offer novel targets for new drugs that
are desperately needed to fight parasitic nematode infections
throughout the world. Targeting PKs in parasites that cause
diseases with high mortality and morbidity, such as malaria, have
recently generated much interest, as recent studies have indicated
specific inhibition of the protozoan kinases can be achieved [11].
Like protozoan parasites, anthelmintic drug development for
nematodes could also benefit from studying nematode kinases.
Kinases are evolutionarily conserved in eukaryotes, and the
nematode Caenorhabditis elegans, has kinase orthologs for over 80%
of the human kinome [4]. Given the large amount of information
already existing for human PKs and kinase inhibitors and the
overlap of kinases between Homo sapiens and C. elegans, kinases in
parasitic nematodes are attractive targets for finding lead
anthelmintic compounds. This strategy of target repurposing has
been explored for initiation and prosecution of neglected disease
drug-discovery programs (e.g. [12]). Furthermore, there are
several examples in the literature where drugs have been also
repositioned (e.g. [13,14]).
By combining a variety of bioinformatics and cheminformatics
approaches, along with laboratory screening on C. elegans and
parasitic nematodes, we were able to learn more about kinomes of
several nematodes spanning the phylum Nematoda. We identified
kinases that are putative good targets, and experimentally test
compounds that have been shown to interact with homologs of
these kinases. Some of the compounds are already being used in
the clinic or are in experimental phases of development for
treating other diseases, making it possible to reposition this drug
for use as a lead compound. For others, we have demonstrated
anthelmintic potential, and due to their specificity, we also provide
insight into pathways within Nematoda that might be important
for drug targeting. Comparison of targets in nematodes and
mammals also reveal opportunities for developing increased
selectivity for nematodes.
Results
The methodology comprised a multi-step process, which
commenced with the predicted proteomes of parasites and their
hosts and resulted in prioritized targets and compounds (Figure 1A).
Classification of Nematode and DrugBank Kinases
PKs from each genome were identified (Figure 1B & Figure S1)
and the 294 orthologous groups containing PKs were phyloge-
netically classified. The 133 PKs previously shown to be shared by
3 nematode species [15] decreased to only 103 (or 68 when only
the manually curated kinases are considered) when the plant-
parasitic Thylenchid, Meloidogyne incognita [16], and the zoonotic
parasite, Trichinella spiralis [17] were included (Figure 1B). The
number of kinases shared among the nematode species could be
underestimated due to the draft nature of the parasitic nematode
genomes. The 68 members of the pan-Phylum conserved kinome
are referred to as the minimal kinome. The minimal kinome is
dominated by kinases from the TK, CMGC, and CAMK groups
(Figure 2A). For each nematode genome, the manually-curated
kinases from the minimal kinome are listed in Tables S1, S2, S3,
S4. The most prevalent groups in C. elegans include: CK1_sub1,
CMGC_sub3, CMGC_sub2, RGC_sub1, and TK_sub2 (Kino-
mer with custom cutoffs) (Figure S2). The most prevalent groups in
B. malayi include CMGC_sub2, CMGC_sub3, TK_sub2,
CK1_sub1, AGC_sub4, and STE_sub1. The largest groups in
H. sapiens include CMGC_sub2, CAMK_sub2, AGC_sub4,
CMGC_sub3, TK_sub2, and AGC_sub4.
The kinases in DrugBank were also characterized in a similar
manner as the nematode kinases. There are 519 compounds in
DrugBank that target one or more of the 299 kinases using kinase
models from Kinomer [7]. Interestingly, CAMK_sub1,
CMGC_sub3, CMGC_sub2, and TK_sub2 all have the largest
number of compounds that bind targets in that group (Figure S2).
Some compounds are very specific for a particular kinase group,
whereas others can bind to targets in multiple kinase groups (Figure 3).
Figure 1. Methodology and pan-phylum kinome characteris-
tics. A. Flow chart of methodology (gray) and compounds and target/
compound elimination (white). B. Distribution of orthologous PK families
among the nematodes spanning the phylum Nematoda. The ortholo-
gous groups were counted before the kinases underwent manual
curation. The number in brackets are kinase genes not in groups C. Of the
C. elegans kinases, orthologous groups were extracted that contain C.
elegans, B. malayi, and H. sapiens. The C. elegans proteins were aligned to
orthologous B. malayi proteins and each of these were aligned to
orthologous H. sapiens. For each pairing, the identities were obtained
through alistat [65]. Dissimilarity plot of nematode and human kinases
using full-length sequence indicate different degrees of dissimilarity
between species among kinase subclasses (e.g CAMK vs CMGC).
doi:10.1371/journal.ppat.1003149.g001
Author Summary
Parasitic nematode infection is a large global health and
economic problem, infecting around 2 billion people and
costing $100 billion in crops and livestock. People in
developing countries often live on one dollar per day, so
treatments cannot be expensive, therefore using pre-
existing drugs as lead compounds provides an economical
way to begin to develop affordable treatments. Protein
kinases were chosen as the focus of this work due to the
large number of pre-existing drugs that target them and
their important role in regulating almost all activities in the
cell. Herein we describe a set of protein kinases conserved
in diverse nematode species and experimental screening
results of pre-existing drugs that target these kinases. The
compounds that show in vitro efficacy in both C. elegans
and parasitic nematodes, H. contortus or B. malayi have
potential to be optimized further. These compounds have
potential to provide accessible treatment to people in
developing countries, as well as improving the health of
livestock and boosting food production globally.
Parasitic Nematodes Kinome
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Primary sequence similarity among nematode full-length PKs is
higher than between nematodes and H. sapiens (Figure 1C),
providing opportunities for specific targeting, despite having
similar active sites. For example, when all isoforms are included,
the 68 groups contain 153 proteins from C. elegans. Using cutoffs
intended to identify kinases that were very different from humans,
an amino acid-based similarity search among nematode and
human kinases yielded 138 C. elegans kinases that were above the
cutoffs, and the remaining 15 had weak homology to H. sapiens.
Even within the conserved orthologous groups, kinases have
substantially diverged in the host (Figure 1C) while still maintain-
ing similar active sites necessary to carry out kinase function.
Furthermore, for example, the dissimilarity level between nema-
tode CAMK members and nematode/human CAMK members
was much larger than between the nematode CMGM and
nematode/human CMGM members (Figure 1C).
Target and Compound Selection
The classification of kinases and compounds that target them
resulted in 116 compounds to screen and many gene candidates as
well. To reduce the number of compounds and potential targets,
only orthologous groups that had a protein conserved across all
four nematode species that span the Phylum were considered
because of their potential for broad control. Using the sixty-eight
orthologous PK groups found in the previous section dramatically
reduced compound search space. Out of 38 total kinase subgroups,
only 28 kinase subgroups had orthologs in all four nematode
species. 22 orthologous groups, spanning 13 kinase subgroups, had
an RNAi phenotype in C. elegans. Of the 22 orthologous groups, 14
(spanning 12 kinase subgroups) also have anatomical expression
data in C. elegans. After considering RNAi phenotypes, nine
orthologous groups were found which had expression in specific
tissues known to be useful for drug targeting (i.e. pharynx [18],
intestine [19], muscle [20] etc) and manifested a RNAi phenotype.
These groups include: TK_sub2, AGC_sub4, CMGC_sub1,
TKL_sub4, STE_sub1, CK1_sub2, TKL_sub2, and
TKLK_sub5. Three other orthologous groups were identified
because the groups had expression patterns conducive to being a
drug target, but did not have an RNAi phenotype: CAMK_sub4,
AGC_sub2, and AGC_sub4. The groups meeting these criteria,
along with RNAi phenotypes, and stage and tissue expression, are
shown in Table S5. RNAi phenotype and phenotype that resulted
from the addition of compound could be different, depending on
the region targeted by RNAi in multiple experiments. A similar
phenotype obtained by the compound and the RNAi screen
indicates that the compound has a mode of action that targets the
same gene the RNAi targets; however, different phenotypes do not
preclude a similar mode of action.
Figure 2. Minimal kinome analysis. A. Nematode minimal kinome compared to C. elegans (Ce), H. sapiens (Hs), DrugBank Targets, and drug target
of each compound in DrugBank. Nematode minimal kinome compared to Ce, Hs, DrugBank targets, and drug target of each compound in DrugBank.
B. Nearest neighbors from the minimal kinome clustered based on KEGG Pathways. The minimal kinome is shown as large circles and the nearest
neighbors are small circles. The nodes are colored based on the KEGG pathways in which they participate.
doi:10.1371/journal.ppat.1003149.g002
Figure 3. Drugs from DrugBank and their interaction with the
different kinase groups. The kinase groups are shown in red, and
the blue nodes indicate compounds that yielded a phenotype in C.
elegans. The grey nodes were tested, but didn’t yield a phenotype.
doi:10.1371/journal.ppat.1003149.g003
Parasitic Nematodes Kinome
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For our compound testing, we wanted to maximize the number
of kinase groups tested with compounds, while also being cost
effective. As a result, major kinase groups that appeared more than
once in the top hit list were eliminated partially based on the
number of compounds that target the subgroup: STE_sub4,
TLK_sub2, and TLK_sub5. TLK_sub2 and STE_sub4 had only
3 and 5 compounds, respectively, associated with them in
DrugBank. Based on the subgroup classification, 116 unique
compounds that target kinases in eight kinase subgroups (Table
S6) were investigated, 35 were prioritized based on cost and
accessibility for experimental testing (Table S7). Specificity was not
used to prioritize compounds.
Compound Screening in C. elegans
The compound screening began with L1-stage worms, which
developed into adult worms over the course of the 72-hour
experiment. Expression of target C. elegans genes over these stages
would be ideal to strongly indicate the target was present for the
compounds to bind. Thirteen compounds exhibited an
EC50,20 ppm and 12 yielded a detectable phenotype. In all, 18
compounds (Figure 4) yielded a detectable phenotype and/or
generated an EC50 less than the maximum dose tested (Table 1).
EC50 values were calculated based on the concentration at which
50% of the nematodes were not moving. Phenotype was not
assessed by EC50. The C. elegans were exposed to five different
concentrations of compound in duplicate, and the effect was
subsequently independently confirmed by a separate experiment
on a different set of worms. An example dose-response curve (for
15) is shown in Figure 5B, and the rest are shown in Figure S3.
Selected videos taken at 20 ppm are included as Supplementary
Videos (Video S1, S2, S3, S4).
Compound Screening in Parasitic Nematodes H.
contortus and B. malayi
The 18 compounds that yielded a detectable phenotype in C.
elegans were also tested in an H. contortus larval development assay.
Three compounds (5, 6, 8) had a MIC90 lower than the maximum
dose tested (Table 1). The dose-response curves are shown in
Figure S4, and the selected videos taken at 20 mM are shown in
the Supplementary Videos (Video S5, S6, S7, S8).
Based on their target specificity in DrugBank, three compounds
(11, 12, 15) with activity in C. elegans were chosen for in vitro testing
in B. malayi for antifilarial activity. Results showed motility was
affected by 15 at 100 mM concentration (by Day 4) (Figure 5D);
the other compounds did not affect motility. In addition, 15
markedly reduced viability by Day 8 and 72–75% reduction in
worm viability was observed in both female and male worms,
respectively (Figure 5E). Compound 15 inhibited microfilaria (MF)
production in a time and concentration-dependent manner. After
2 days in culture with 15, female worms showed greater than 50%
inhibition in MF release at high concentrations (100 mM). By Day
8, 10 mM appeared to be the minimum effective concentration
that could inhibit MF release from female worms. Although there
was no effect on motility and viability, a 50% reduction in MF
release was observed by 12 at Day 6 (Figure S5).
Discussion
Therapies are desperately needed to combat parasitic nematode
infections, which plague over 2 billion people or 1/3 of the earth’s
population [21]. Since helminth infections are endemic in
developing countries, we explored possible repositioning of
existing drugs for use as lead compounds, as using a pre-existing
drug lowers substantially the cost of drug development. The
nematode kinome is a rich resource for exploring compounds that
may show anthelmintic activity due to the wealth of existing
information on PKs and PK inhibitors. The lead compounds
found via repositioning could be modified to increase efficacy.
Using a pan-phylum compilation of nematode proteomes, kinases
were identified and classified into groups and subsequently into
subgroups. Kinases in DrugBank were also identified and classified
into groups/subgroups. Compounds were linked to targets via the
subgroup classification, and disparate information regarding the
kinase targets was combined to prioritize the targets (and
associated compounds) for experimental testing. A total of 35
compounds were tested in C. elegans, and 18 exhibited a deleterious
phenotype.
With our upfront prioritization and characterization, our study
had a much higher hit rate with respect to C. elegans nematodes
(51%), compared to a previous study where high-throughput
screening of ,14,000 compounds was done and resulted in 308
compounds yielding phenotypes (2.2% success rate [22]). Out of
the ,14,000 compounds 483 are likely to be kinase inhibitors in
the entire library based on a cheminformatic search using a
Tanimoto score of 0.8 (3.45%), and of the 308 displaying
phenotype (3.24%) 10 were kinase inhibitors. Our hit rate was
18/35 (,51%) compared to the HTS approach 10/483 (2.1%),
resulting in a 256 enrichment. While the difference in the
concentration used by the two studies (,25 mM versus 20 ppm
Figure 4. Structures of compounds that elicited a phenotype in
C. elegans. 1 (DB00773) Etoposide, 2 (DB02709) Resveratrol, 3
(DB04604) 5-iodotubercidin, 4 (DB03615s) Neomycin, 5 (DB02152) K-
252a, 6 (DB02010) staurosporine, 7 (DB03023) PP2, 8 (DB04707)
HA1077, 9 (DB04080s) Tropic Acid, 10 (DB03684) 2-methyl pentanediol,
11 (DB03693) N-(2-Aminoethyl)-5-Chloroisoquinoline-8-Sulfonamide,
12 (DB02984) 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline,
13 (DB02175) malonic acid, 14 (DB02908s) Benzylphosphonic Acid,
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(,25 to 60 mM, depending on the molecular weight of the
compound)) could in part be responsible for the observed
enrichment, our prioritization approach highly enriches for good
potential candidates. Only two of our compounds tested
overlapped with the high-throughput screening study [22]; 2
caused jerky and abnormal movements in C. elegans, and the other
(DB01953) did not produce a phenotype. Furthermore, our
strategy used species that span the phylum, increasing the
possibility of identifying candidate targets for broad control.
At the root of our study was i) identification of the kinome
within each of the nematode species, and ii) identification and
characterization of a minimal kinome, or group of kinases that are
conserved among species that span the phylum Nematoda. The 68
pan-phylum nematode PK orthologous groups spanned 9 different
PK groups (TK, AGC, CMGC, TKL, STE, CAMK, CK1, RIO,
and RGC) and 28 subgroups (Table S4) out of a possible 12 groups
and 38 subgroups. These kinases were linked to kinases in
DrugBank based on their subgroup classification. A representative
of each of the ePK groups is present in the minimal kinome, but
some groups were more highly represented in the minimal kinome
than others (Figure 2A), with CMGC being the most highly
represented (21.6%). The highest reduction in parasitic nematodes
versus free-living was detected in the Receptor Guanylate Cyclases
(RGC) that has been shown to be expanded in several metazoans,
most dramatically in Caenorhabditis species [23]. Based on our
analysis, there is a drastic reduction of this class in the parasitic
nematodes compared to C. elegans, especially in the human
parasites T. spiralis (2%) and B. malayi (1.7%) vs C. elegans (5.1%)
(Figure S1). The nematode kinase groups had corresponding drug
targets (by associations because drug targets were classified the
same way) and drugs in DrugBank. DrugBank has nearly twice as
many TK targets, most likely due to their prominence as cancer
targets. However, DrugBank had nearly two fold more compounds
that target CAMK proteins relative to the total number of
compounds and targets, which is mainly caused by a large number
of compounds targeting CAMK_sub1 (Figure S2).
Over 65% of the minimal kinome that successfully maps to the
major KEGG pathways are involved in Environmental Informa-
tion Processing including the MAPK, Wnt, mTOR, or ErbB
signaling pathways (Figure 2B); however, only 34% of the minimal
kinome can be mapped to the KEGG pathways. When the
minimal kinome is mapped to KEGG pathways along with the
proteins with which they interact, the vast majority are involved in
genetic information processing or a combination of different
pathways (Figure 2B). The entire C. elegans minimal kinome maps
to all five major KEGG pathways; however, individual kinase
groups often lack a specific major pathway. For instance, TK and
RGC are the only groups that map to metabolic pathways and
CAMK and TK do not map to any genetic information processing
pathways (Figure S6).
The second phase of our study involved linking compounds in
DrugBank to kinases in nematodes that were conserved across the
phylum. This study did not bias the results toward kinase
inhibitors, rather all compounds in DrugBank were considered if
the target made the appropriate cutoff. Thus, some compounds
are not typical kinase inhibitors, but had experimental evidence for
binding to a kinase. These compounds were tested so as to not
throw away potential lead compounds, even though they were not
typical kinase inhibitors. The 18 compounds that yielded a
phenotype in C. elegans provide excellent lead compounds that
could be developed into anthelmintic drugs. Further, 6 of the 18
compounds also showed efficacy against at least one of two very
Table 1. Compound screening in C. elegans, H. contortus, and B. malayi.
C. elegansa H. contortus B. malayi
Comp Num DrugBank ID Common Name C. elegans (EC50 mM) Pheno (MIC90 mM) (MEC mM)b
1 DB00773 Etoposide .34.0 + .20
2 DB02709 Resveratrol .87.6 + .20
3 DB04604 5-iodotubercidin 2.6 + .20
4 DB03615c Neomycin 9.7 + .20
5 DB02152 K-252a 15.3 2 1.3
6 DB02010 Staurosporine 0.7 2 5
7 DB03023 PP2 46 + .20
8 DB04707c HA1077 28.4 2 20
9 DB04080c Tropic acid 120.4 2 .20
10 DB03684 2-Methyl-2,4-Pentanediol 123.5 + .20
11 DB03693 N-(2-Aminoethyl)-5-Chloroisoquinoline-8-Sulfonamide .70.0 + .20 .100
12 DB02984 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline .61.1 + .20 100
13 DB02175 Malonic Acid .192.2 + .20
14 DB02908c Benzylphosphonic acid 63.5 2 .20
15 DB03044 BIRB 796 36.3 2 .20 10
16 DB01254 Dasatinib 22.3 2 .20
17 DB01933 KT-5720 36.9 + .20
18 DB03496 Flavopiridol 48.3 + .20
aC. elegans Phenotype 72 hrs post treatment: jerky or slow movement, twitchy, and combination of these.;
bMinimum effective concentration where effect is seen in 50% of worms;
cSimilar to DrugBank compound within a Tanimoto similarity score of 0.8.
doi:10.1371/journal.ppat.1003149.t001
Parasitic Nematodes Kinome
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different nematode species, the blood-feeding H. contortus and the
filarial B. malayi. The difference in lifestyle between C. elegans and
the parasitic nematodes is quite large, making the finding that
these 6 compounds are more broadly applicable to the entire
phylum. However, differences in the species could also lead to a
large difference in compound potency across the species, as the
species have different uptake mechanisms. Further, the screening
on the various species included different life stages, which could
also lead to differences in compound potency. Several of these
compounds that were hits in C. elegans are already FDA approved
drugs used as antimicrobials and/or cancer drugs. One example is
16 (Dasatinib), an approved small molecule that targets BCR/Abl
in chronic myloid leukemia, which exhibited deleterious effects on
worms yielding an EC50 of 22.3 mM. Flavopiridol, 18, is an
experimental treatment for cancer that also yielded an EC50 of
48.3 mM. Neomycin, 4, is an antibacterial compound that yielded
an EC50 of 9.7 mM. Etoposide, 1, is an approved small molecule
and has antitumor activity which caused jerky/abnormal move-
ments in C. elegans. These compounds have already extensive
toxicity data for humans associated with them (16 [24,25]; 18 [26–
28]; 4 [29]; 1 [30–33]).
Detailed examination of the results, allowed formation of
hypotheses regarding the pathways in which the targets are
involved and the compounds might be affecting. It is not surprising
that the pathways are hard to deconvolute based on looking at
compound-protein interactions. Of 276,122 bioactive compounds,
35% were known to bind to multiple targets, and surprisingly,
25% of these bind to proteins in different gene families [34]. In
cases such as TK_sub2, the targets are all very similar even though
this is a particularly large group. Within TK_sub2, 13 compounds
were tested, and 7 of them yielded an EC50 .20 ppm and/or a
phenotype in C. elegans. Oftentimes, the compounds are able to
target several different kinases within this group, making it
particularly difficult to discern a precise targeted protein or
pathway.
For all the compounds, additional studies need to be done to
completely confirm the compounds’ mode of action. However,
three subgroups of kinases, which had compounds that were likely
to specifically target a particular enzyme, provide useful hypoth-
eses into the compound’s mode of action for further study. The
first group is CMGC_sub1, which is a kinase group that contains
predominately CDKs (cyclin dependent kinase) and MAPK
(mitogen-activated protein kinase). Of the 14 C. elegans proteins
in this group (cutoff 1e25), 4 were conserved among T. spiralis, B.
malayi, and M. incognita. These conserved C. elegans kinases are
B0285.1 (cdc2 kinase), B0205.7 (casein kinase II), F43C1.2
(ERK5), and B0478.1 (JNK). From DrugBank, there are 14 drug
targets that are classified in CMGC_sub1. Out of the eight
compounds tested that target this group, two compounds, 12 and
15, showed efficacy and specifically target p38 based on literature
Figure 5. Alignment, structure, and experimental data for p38 MAP kinase (CMGC_sub1). (A). 1KV2 with 15 bound. Residues that differ
between mammals and nematodes within 5 A˚ of the active site are colored in grey, and residues within 10 A˚ are shown in blue. The compound is
colored yellow. (B). Dose-response curve of 15 in C. elegans. (C). Expression data from B. malayi microarray data [66] for p38 orthologs in B. malayi.
(D). Percent reduction in microfilarial release in B. malayi cultured with 15 in vitro. (E). Percent reduction in viability in B. malayi female and male
worms cultured with 15. (F). 1KV2 alignment of Tsp_3128 (T. spiralis), Mh10g200708_Contig883_17801_19594 (M. hapla), 14956.m00538 (B. malayi),
B0218.3 (C. elegans), CBN12041 (C. brenneri), CBG01555 (C. briggsae), NP001095644.1 (B. taurus), ENSP00000229795 (H. sapiens), EN-
SMUSP00000004990 (M. musculus), P70618.3 (R. norvegicus), NP_001003206.1 (C. familaris), 1KV2. Residues 5 and 10 A˚ from the compound in the
active site are starred. Differences in the active site are represented by larger red star at the bottom.
doi:10.1371/journal.ppat.1003149.g005
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searching and DrugBank listings. In a previous study [35], 15
bound to several of the H. sapiens orthologs of C. elegans proteins in
the minimal kinome: B0285.1 (1100 nM), F43C1.2 (2500 nM),
B0478.1 (9100 nM and 7.3 nM). However, 15 binds to the H.
sapiens ortholog of B0218.3 (NP_620581.1) at a much higher
affinity (0.45 nM), increasing the likelihood that B0218.3 is the
main target in our C. elegans screen. The proteins with which
B0218.3 interacts include those involved in organismal systems
and environmental information processing and are also differen-
tially over-expressed during stages in which the compound
screening assay was carried out (Figure 6A & C).
The p38 kinase, B0218.3, is only conserved among C. elegans and
the vertebrate parasites (B. malayi and T. spiralis); it was not present
in the minimal kinome because a p38 ortholog is not found in the
plant parasite, M. incognita. Inhibitors of p38 have shown promise in
fighting other parasite infections [36–39]. Our results suggest that
p38 may be a good target for other filarial parasitic nematodes
species as well. Structural analysis can be done, as X-ray crystal
structures exist of 12 and 15 bound to p38. Although most residues
in the active site are conserved between mammals and mouse, some
nearby residues differ (Figure 5A & C and Figure S5A & S5B),
creating opportunities for development of more specific drugs.
Further, 12 and 15 were tested in B. malayi adult worms and were
found to have an effect. The expression results [40] also support the
sex-dependent effect on worm motility in B. malayi. 12 caused a
reduction in worm viability in female worms, but caused no
reduction in male worms (Figure S5C–E). 15 caused a reduction in
worm viability in female worms at a much lower concentration than
in male worms (Figure 5C–E). Compound 15 is currently in phase
III clinical trials for rheumatoid arthritis and Crohn’s disease [41].
The second group for which the mode of action could be
hypothesized is CK1_sub2, providing an excellent basis for further
experimental testing. Involved in key regulatory processes [42],
casein kinase 1 has been shown to be an important drug target for
various parasitic species [43–46] (Figure S7). Out of the 3
compounds tested that target this group, 2 compounds, 11 and 3,
showed efficacy. Compound 11 specifically targets casein kinase 1
from CK1_sub2. Compound 11 did not yield an EC50 value, but
appeared to have jerky movement. Compound 3 binds casein
kinase 1, as well as ser/thr protein kinase haspin and MAPK3,
yielding an EC50 value of 2.6 mM and resulting in worms that
move slowly and are smaller and less developed. X-ray crystal
structures are available: 3 bound to CK1 in Saccharomyces pombe and
11 bound to H. sapiens CK1-gamma (Figure S8). Comparing their
sequence to C. elegans proteins that were classified into CK1_sub2,
the sequence of the X-ray crystal structure most closely resembles
Y106G6E.6, making it likely that the compounds bind to this
protein and its other casein kinase I gamma nematode orthologs
(Figure S7). Further, Y106G6E.6 is also differentially over-
expressed in late embryo, L2, and young adult stages
(Figure 6D), which include stages during which the screening
experiment was done. The results from B. malayi further point to
the compound targeting its CK1 alpha orthologs. Compound 11
did not pass the threshold for causing a 50% reduction in motility,
but came very close in males with 41.6% reduction in viability in
males at 100 mM concentration. (Figure S9). Given the effect was
sex-associated, it is likely that 11 is also targeting the CK1 alpha
orthologs (Figure S7).
The third group that had a compound that specifically targeted
one enzyme is AGC_sub2. One hit from this group, 17, selectively
Figure 6. PPIs fromMINT mapped using PPIs from C. elegans and C. elegans orthologs from D. melanogaster and S. cerevisiae. PPIs for A.
B0218.3 and C. Y106G6E.6 color coded and grouped based on KEGG pathway assignment. PPIs for B. B0218.3 and D. Y106G6E.6 color coded by
expression levels from RNAseq data. The proteins involved in pathways connected to B0218.3 are linked to several different pathways, including
genetic information processing. MAPKs play important roles in signal transduction and are involved in cellular processes such as proliferation,
differentiation, and cell survival in eukaryotes. B0218.3 is differentially over-expressed in the late embryo (LE) and L1–L3 stages (p,0.1) based on our
analysis of C. elegans expression data [59].
doi:10.1371/journal.ppat.1003149.g006
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inhibits Protein Kinase A (PKA). Compound 17 is not in
DrugBank, but was chosen for testing because of its similarity to
DB01933 and the inability to obtain DB01933. DB01933 targets
AGC_sub4, but 17 is a known inhibitor of PKA, which is in
AGC_sub2. Not only did 17 yield an EC50 when added to C.
elegans, the worms also displayed jerky, slowed, and twitching
movements on the test plate, in addition to being smaller.
Interestingly, siRNA was used to knockdown a splice variant of
PKA, causing paralysis in the C. elegans adult stage [47].
Compound 17 is a derivative of 5 and 6 which target other
kinases non-specifically. Compound 8 (similar to DB04707 –
hydrofasudil) also targets PKA, but also inhibits Rho-associated
protein kinase (ROCK), as well as several other targets not listed in
DrugBank (protein kinase G, NADPH oxidase, myosin light chain
kinase, etc). Compound 8 is already used to treat cardiovascular
disease [48] and has the potential to be a promising therapy to
manage severe malaria [49]. PKA has been suggested as a good
drug target in the filarial nematode, Onchocerca volvulus [50], and in
the protozoan, P. falciparum [51].
In this study, we have classified kinases in several different
nematode species, C. elegans, B. malayi, T. spiralis, and M. incognita,
which span several phylogenetic clades and lifestyles (free-living
and parasitic) in the phylum Nematoda. The proteins were placed
in orthologous groups, and 68 orthologous groups had proteins in
each of the nematode species, indicating those proteins are
conserved and therefore important for nematode survival. Drug
targets in DrugBank were also classified, and compounds that bind
to DrugBank targets were matched with promising nematode
proteins via kinase classification. Several PK inhibitors, which are
currently being used in the clinic or in experimental phases of
development for other diseases, were tested and shown to have
efficacy in C. elegans, H. contortus and/or B. malayi. For the
compounds that show efficacy, we also made hypotheses about
their mode of action via bioinformatic and structural analysis and
provide some insight into how to improve specificity for the
nematode versus mammalian protein in several cases.
Materials and Methods
A flowchart of the methodology is shown in Figure 1.
Ethics Statement
All animals were handled in accordance with guidelines defined
by the Animal Welfare Act (A3381-01), Association for Assessment
and Accreditation of Laboratory Care International (AAAALAC),
PHS Policy for the Humane Care and Use of Laboratory Animals,
the Guide for the Care and Use of Laboratory Animals, and the
Division of Comparative Medicine, Washington University School
of Medicine. All animal work was approved under WUSM
Institutional Animal Care and Use Protocol 20120025.
Classification of Nematode and DrugBank Kinases
Kinase domain models were downloaded from the Kinomer
website (http://www.compbio.dundee.ac.uk/kinomer/allPK.
hmm) and were used to screen a collection of gene sets from the
organisms Brugia malayi, Caenorhabditis elegans, Drosophila melanogaster,
Homo sapiens, Meloidogyne incognita, Saccharomyces cerevisiae, and
Trichinella spiralis. Custom score thresholds per kinase group were
taken from Miranda-Saavedra [7] and then adjusted until an
hmmpfam search (HMMER v2.3.2) came as close as possible to
identifying all known C.elegans kinases using the Kinomer
allPK.hmm profile database. Those same cutoffs were then
applied to the gene sets of the remaining 6 organisms, identifying
sets of putative kinases in each case. These putative kinases were
categorized into the 8 conventional kinase groups (ePK) and the 4
atypical kinase groups (aPK) by merit of which model they were
found to hit in the Kinomer profile database (allPK.hmm).
We then manually curated the sets of putative kinases by
screening them against Pfam using hmmpfam (as a part of an
interproscan run (interproscan software v4.5, interpro db release
2.2)) and making sure that no clear contradictions were found. Any
cases where a putatively identified kinase was found to have a
clearly non-kinase Pfam domain hit, were removed from the final
set of identifications. The custom cutoffs used per kinase group
were as follows: TK, 5.5e-03; CAMK, 9.6e-07; CK1, 1.1e-02;
CMGC, 6.7e-03; AGC, 1.1e-14; STE, 3.4e-03; RGC, 4.8e-05;
TKL, 8.7e-03; PDHK, 4.7e-160; PIKK, 1.4e-06; Alpha, 8.5e-66;
RIO, 7.5e-10.
The same methodology used to classify the nematode kinases
was also used to classify targets in DrugBank. DrugBank v2.5 was
used to screen against the kinase domain models using an E-value
cutoff of 0.1. If the target in DrugBank and a nematode kinase
were classified into the same kinase subgroup by the HMM, the
nematode protein by association was hypothesized to interact with
one of the drugs in DrugBank known to bind a particular target.
Prioritization of Kinases to Test
OrthoMCL [52] was used to group the 6 proteomes (B. malayi,
D. melanogaster, M. incognita, T. spiralis, S. cerevisiae, C. elegans) into
orthologous groups using a default inflation factor of 1.5 (all
othologous groups are available at Nematode.net [53]). To
determine the best kinase groups which have compounds that
target them, the kinase groups were evaluated as to whether they
exhibited an RNAi phenotype and if there was tissue expression
data in C. elegans. RNAi phenotypes for C. elegans (http://www.
wormbase.org/#012-3-6, WS220; downloaded on April 19, 2011)
were grouped based on Kumar et al. [54]. The complete list of
RNAi phenotypes, sorted by bin, are available as Table S2 in
Taylor, et al. [55]. Tissue expression for C. elegans was obtained
from Wormmart [56] on April 23, 2010. GO associations of the all
helminth proteins were made by running InterProScan [57]
(release 4.5). EST [58], tissue localization, and RNAseq data [59]
were also used to evaluate potential groups for compound testing.
Protein-protein Interactions and Pathway Information
Protein-protein interactions from MINT [60] were found for C.
elegans, S. cerevisiae, and D. melanogaster. Using the protein
orthologous groups obtained from the OrthoMCL clustering, the
protein-protein interactions in C. elegans were expanded using
orthologous protein-protein interactions in S. cerevisiae and D.
melanogaster. Cytoscape [61] was used to analyze the networks, and
the multicolor node plugin [62] was used to analyze kinase
classification and expression values.
Compound Screening in Caenorhabditis elegans
Compounds for experiments were obtained from the following
sources (compounds obtained are shown in parenthesis): Enzo
LifeSciences (1,2,4,7,8,14,17), Ryan Chemicals (9, 10, 11, 12, 13,
15), and LC (5,6) and TRC (3,16,18). Some of the compounds
were not found commercially, so these compounds were substi-
tuted with available compounds with the highest similarity assessed
via Tanimoto score of 0.8 or greater, which was calculated using
OpenBabel [63]. Compound screening commenced with L1 stage
worms and ran for 72 hrs at which point the C. elegans were around
adult stage, so expression of the conserved C. elegans genes over the
course of the experiment is required to maximize the effect of the
compound on the organism. RNAseq data was taken into account
when selecting compounds to test, but was not used to limit the
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compounds tested. For example, genes expressed during the early
embryo stage may not be functional until the L1 stage. Thirty-five
compounds were chosen for testing in C. elegans based on
compound availability and cost at various vendors.
Compounds formulated in 100% DMSO were tested in
microtiter plates containing 50 ml nematode growth media, 1%
E. coli and 20 L1 C. elegans. The efficacy of a compound was
determined based on the motility of the larvae as compared to
average motility of control wells containing DMSO only at
48 hours post treatment. Larval movement was manually assessed
at 72 hours post treatment to determine if there were altered
movements or morphological changes not detected by the imaging
system. C. elegans was exposed to the five different concentrations
(0.08–20 ppm;,25 to 60 mM, depending on the molecular weight
of the compound) and two replicates, and the effect was
subsequently confirmed by an independent test.
Compound Screening in Haemonchus contortus
Compounds were screened in H. contortus after formulation in
100% DMSO. The testing was performed in microtiter plates
containing 50 ml nematode media, fecal slurry and 20 L1 H.
contortus. H. contortus was exposed to five different concentrations
(0.08–20 mM). The efficacy of a compound was determined based
on the motility of the larvae as compared to average motility of
control wells containing DMSO only. A MIC90 value was
calculated by determining the lowest dose at which there was a
90% reduction in motility as compared to the control wells. Larval
movement was manually assessed at 72 hours post treatment to
determine if there were altered movements or morphological
changes not detected by the camera.
Compound Screening in Brugia malayi
B. malayi adult male and female worms were obtained from the
peritoneal cavities of male gerbils infected with third-stage larvae
at 120 days post-infection with third stage larvae. Worms were
washed 3 times with RPMI-1640 to eliminate host cell contam-
ination and then washed 3–4 times with RPMI containing 200 U/
ml streptomycin, 100 mg/ml penicillin, and 0.25 mg/ml of
amphotericin-B (Sigma).
Effect of 3 kinase inhibitors on parasite motility and
viability. Effect of inhibitors were studied by incubating two
adult female and male worms (4) in 2 ml of either culture medium
(CM) alone or in CM with added compounds dissolved in solvent
DMSO in 24 well culture plates. Final concentration of DMSO in
CM was less than 1%. Control cultures with worms were set up
with different dilutions of solvent in medium only, and additional
worm cultures included only 2 ml of culture medium. Compounds
were added to the culture medium at a final concentration of
5 mM, 10 mM, 20 mM, 50 mM and 100 mM. The culture medium
was replaced with fresh medium with compounds on alternate
days and all cultures were terminated on day 8. The worm cultures
with or without compounds were carried out in duplicate and
results were expressed as means of the replicate experiments [64].
Parasite motility. Parasite motility and death was assessed
visually by microscopy and the observations were scored as 0,
immotile or dead; 1, slightly active; 2, active and motile; 3,
moderately active and motile; and 4, highly active and motile
(equal to the activity and motility of worms cultured in culture
medium without added compounds).
MTT reduction assay. Parasite (adult worm) viability was
assessed quantitatively by the MTT reduction assay [64]. Briefly,
single worms were placed in 0.5 ml of PBS containing 0.5 mg/ml
of MTT and incubated at 37uC for 1 hr. At the end of the
incubation time, worms were removed and carefully transferred
into a separate well of microtiter plate containing 200 ml of
DMSO and kept at room temperature for 1 hr. The absorbance of
the resulting colored product was then determined at 490 nm
wavelength using a microplate reader. Dead worms that had been
heat killed and doxycyline (10 mg/ml) killed were used as negative
controls for MTT reduction experiments. The minimum concen-
tration of compound that caused .50% reduction in MTT test
was considered as significant.
Microfilaria Counts
Adult female worms incubated in CM released MF in vitro under
the culture conditions tested. MF released into the CM counted in
duplicate 20 ml aliquots on 2, 4, 6 and 8 days post-culture. Results
were expressed as the percent reduction in MF release relative to
results obtained with control worms cultured in CM without
added compounds.
Supporting Information
Figure S1 Distribution of PKs per major families in
distinct nematodes and humans. C. elegans (Ce), H. sapiens
(Hs), B. malayi (Bm), T.spiralis (Ts), M. incognita (Mi).
(EPS)
Figure S2 Number of total kinases within each species/
group of compounds. The curated kinases were considered for
the species. Each compound that mapped to an identified kinase
target in DrugBank via HMM was considered (cutoff 0.1). The
compounds that target a protein in each group were counted.
(EPS)
Figure S3 Example C. elegans dose response curves for
each compound.
(EPS)
Figure S4 Example H. contortus dose-response curves
for each compound.
(EPS)
Figure S5 Alignment, structure, and experimental data
for p38 MAP kinase (CMGC _group1). A. 1DI9 with
DB02984 bound. Residues within 10 A˚ of the active site that differ
between mammals and nematodes are colored in grey. B. 1DI9
alignment of Tsp_03128 (T. spiralis), Mh10g200708_Con-
tig883_17801_19594 (M. hapla), 14956.m00538 (B. malayi),
B0218.3 (C. elegans), CBN12041 (C. brenneri), CBG01555 (C.
briggsae), NP_001095644.1 (B. taurus), P70618.3 (R. norvegicus),
ENSMUSP00000004990 (M. musculus), ENSP00000229795 (H.
sapiens), NP_001003206.1 (C. familiaris), 1DI9. C. Expression data
from B. malayi microarray data [66] for p38 orthologs in B. malayi.
D. Percent reduction in microfilarial release in B. malayi exposed to
Compound 12 in vitro. E. Percent reduction in viability in B. malayi
when exposed to Compound 12.
(EPS)
Figure S6 Kinases in C. elegans (cutoff 0.1) mapped to
the major KEGG pathways.
(EPS)
Figure S7 Tree of CK1 alpha and gamma with distance
calculated using percent identity. Compound 11 was found
to also inhibit TcCK1.1 in T. cruzi in vitro [45], as well as
aminoglycoside kinase in Legionella pneumophila [46]. A sequence
comparison revealed that TcCK1.1 is closer to CK1 alpha than
CK1 gamma. At this time, there is no data available for 11
binding CK1 alpha in H. sapiens. Given the results with T. cruzi, the
11 may be targeting the CK1-alpha-like nematode proteins,
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C03C10.1 and F46F2.2 as well, which could provide further
opportunities for specific targeting.
(EPS)
Figure S8 Alignment and structure of casein kinase I
(CK1_group2). A. Structure of 2C47 (H. sapiens casein kinase I
gamma2) with 3 bound (green). The structure of 2CSN (S. pombe
casein kinase I) was superimposed with 2C47 using Pymol [67].
2CSN has 11 bound (yellow). The residues that differ between
mammals and nematodes are highlighted in grey. Sequence
analysis between mammals and nematodes revealed some subtle
differences within 10 A˚ that could be potentially exploited to make
a slightly more specific compound. B. Dose-response curve of 3 in
C. elegans. C. The alignment of prot_Minc02294 (M. incognita),
Mh10g200708_Contig69_9047_6539 (M. hapla), 14971.m02829
(B. malayi), CBN30117 (C. brenneri), CBG12215 (C. briggsae),
CRE23960 (C. remanei), Y106G6E.6 (C. elegans), Tsp_05423 (T.
spiralis), ENSP00000307753 (H. sapiens), ENSMUSP00000082561
(M. musculus), EHH54474.1 (M. fascicularis), NP_001094526.1 (B.
taurus), and NP_001029042.1 (R. norvegicus).
(EPS)
Figure S9 Expression of B. malayi orthologs for casein
kinase I and results from testing Compound 11 in B.
malayi. A. Expression data from B. malayi microarray data [66]
for casein kinase I alpha orthologs in B. malayi. B. Percent
reduction in viability in B. malayi male and female worm exposed
to Compound 11 in vitro. Two B. malayi orthologs of CK1 alpha,
14972.m07128 and 14979.m04526, were much more highly
expressed in males versus females (log ratio of 0.68 and 0.61,
respectively, compared to an average log ratio of 20.13 and 0.15,
respectively). However, the B. malayi ortholog of CK1 gamma
(14971.m02829) was much more highly expressed in female and
MF (log ratio of 0.48 and 0.82, respectively compared to an
average log ratio of 20.07) [40].
(EPS)
Table S1 The B. malayi kinases in the minimal pan-
phylum containing the 68 orthologous groups. Multiple B.
malayi proteins exist in some orthologous groups. The KO,
Interpro, and GO ids to which the protein was mapped are also
listed.
(XLSX)
Table S2 The M. incognita kinases in the minimal pan-
phylum containing the 68 orthologous groups. Multiple M.
incognita proteins exist in some orthologous groups. The KO and
GO ids to which the protein was mapped are also listed.
(XLSX)
Table S3 The T. spiralis kinases in the minimal pan-
phylum containing the 68 orthologous groups. Multiple T.
spiralis proteins exist in some orthologous groups. The KO and
GO ids to which the protein was mapped are also listed.
(XLSX)
Table S4 The C. elegans kinases in the minimal pan-
phylum containing the 68 orthologous groups. Multiple C.
elegans proteins exist in some orthologous groups. A description of
the protein, the KO and GO ids to which the protein was mapped
are also listed. Tissue expression as well as RNAi classification in
C. elegans are also listed.
(XLSX)
Table S5 The top orthologous groups from the minimal
kinome listed with the respective C. elegans protein, the
kinase classification, E-value from the HMM, DrugBank
target ID and compounds known to bind to the target,
KO and IPR IDs, information regarding tissue expres-
sion in C. elegans, RNAi phenotype, and stage expres-
sion RNAseq data analyzed within a stage and across
different stages.
(XLSX)
Table S6 Top orthologous groups, the drug bank
compound ids associated with the targets within the
orthologous group, drug common name, drug use,
treatment the drug is used to treat, and category of the
drug.
(XLSX)
Table S7 Compounds tested in C. elegans, catalog
number used, kinase classification of compounds target
from drug bank, the phenotype the compound caused in
C. elegans, and the EC50 results in C. elegans listed in
ppm concentrations.
(XLSX)
Video S1 C. elegans control.
(WMV)
Video S2 C. elegans exposed to compounds 5.
(WMV)
Video S3 C. elegans exposed to compounds 6.
(WMV)
Video S4 C. elegans exposed to compounds 8.
(WMV)
Video S5 H. contortus control.
(WMV)
Video S6 H. contortus exposed to compound 5.
(WMV)
Video S7 H. contortus exposed to compound 6.
(WMV)
Video S8 H. contortus exposed to compound 8.
(WMV)
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